ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~4#܈ ~~<#܈ ~~3#܈ ~~"؈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33 FORM 10Q lINDEX& Balance SheetCIncome Statementh Cash FlowsNOTE 4 INVENTORY"NOTE 5 OTHER CURRENT ASSETS՛NOTE 6 FIXED ASSETSըNOTE 7 INTANGIBLE ASSETS&~NOTES TO UNAUDITED CONSOLIDATEDBNOTES TO UNAUDITED (1)&NOTE 8 OTHER CURRENT LIABILITIE uNOTE 9 NET LOSS PER SHARErNOTES TO UNAUDITED (2) NOTES TO UNAUDITED (3)XNOTES TO UNAUDITED (4)TX001HR&.Research and Development Expens&=Three months ended June 30 2017KOperating ExpensesqXOperating Expen (1)&Sg29 Six months ended June 30 201auOperating Expen (2)Operating Expen (3)&Summary of Uses and Sources of qItem 6 Exhibits© SIGNATURES&CERTIFICATION OF CHIEF EXECUTIV&CERTIFICATION OF CHIEF FINANCIA&{SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1) l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??INDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 6} $ } !      TherapeuticsMD, Inc. 10-Q 08/03/2017 FORM 10-Q!Large accelerated filer ?Accelerated filer ? Non-accelerated filer ? # Smaller reporting company ?5 -(Do not check if a smaller reporting company) ! Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,u%eYM%=PF0*8X> @  l  1=!_&  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10Q Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } y } y<}  1     TherapeuticsMD, Inc. 10-Q 08/03/2017 INDEX Page& PART I - FINANCIAL INFORMATION       Item. 1 Financial Statements       . &Consolidated Balance Sheets as of June~ 2*30, 2017 (Unaudited) and December 31, 2016-%Consolidated Statements of Operations~ 3+for the Three and Six Months Ended June 30,-%2017 (Unaudited) and 2016 (Unaudited)-%Consolidated Statements of Cash Flows~ :2for the Six Months Ended June 30, 2017 (Unaudited)and 2016 (Unaudited)2*Notes to Consolidated Financial Statements~ Item 2.,$Management?s Discussion and Analysis~ V80of Financial Condition and Results of OperationsItem 3.0(Quantitative and Qualitative Disclosures~ about Market RisksDB ly]'|$O0r5 !"#$%&'()*+,-./0  Item 4. Controls and Procedures~ !!!!#"Part II - OTHER INFORMATION~ "####$$Item 1.$Legal Proceedings~ $%%%%&&Item 1A.& Risk Factors~ &''''((Item 2./('Unregistered Sales of Equity Securities~ ()))and Use of Proceeds****++Item 6.+Exhibits~ +,-$.____________________________1/)Created by Morningstar Document Research.00(http://documentresearch.morningstar.com/&@K[+d# =PF0*8X> @*00//..""  l  87B  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEXIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 8} $ } y} $ } y} $ 8                                 TherapeuticsMD, Inc. 10-Q 08/03/2017 Balance Sheet June 30, 2017December 31, 2016    (Unaudited)            ASSETS  Current Assets:         Cash~ u~ V4\-%Accounts receivable, net of allowance~ M~ n7/for doubtful accounts of $358,268 and $376,374, respectively Inventory~ MV~ AOther current assets~ N~ RTotal current assets~ b~  @7766552222!!!!   l  -$_g  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance Sheet Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0} $ }  } $ } y}  $ } y} $ } y} $ -     TherapeuticsMD, Inc. 10-Q 08/03/2017Income StatementThree Months Ended  Six Months Ended   June 30,   June 30,  ~   ~   ~   ~                     Revenues, net ~ m  ~    ~   ~ j9                  Cost of goods sold~ )~ D  ~  Q  ~ ^      Gross profit~ ~   ~  &Ϥ  ~      Operating expenses:     *"Sales, general, and administration~ |~ !  ~    ~ Z Research and development~ ~ L  ~  N~  ~ ?%Depreciation and amortization~ ?~ {  ~  G  ~ NTotal operating expense~ !~ i  ~  Vr   ~ .ʿ      Operating loss~ VE~ ]  ~  zx2  ~ =      Other income:     Miscellaneous income~  ~ B  ~  :  ~  Accreted interest~ ;~ ,  ~  Nx  ~ ^TTotal other income~ T ~ &  ~  A  ~       Loss before taxes~ .O~   ~  C  ~ Dlzn0!Uv >e} !"#$%&'()*+,                 "!Provision for income taxes!! !?!!! !?!! !  ! ?! ! ! !?!"""""""""" " " " " """#Net loss#~ #.O##~ ### ~ # C# # ~ ##$$$$$$$$$$ $ $ $ $ $$$-%%Net loss per share, basic and diluted%%%%%)\(%% % ɿ% % %zGʿ%&&&&&&&&&& & & & & &&&0'(Weighted average number of common shares''~ '}0'''~ 'N.'' ' ~ ' j/' ' '~ 'O.'( outstanding)$*____________________________1+)Created by Morningstar Document Research.0,(http://documentresearch.morningstar.com/S4J~-aeNB=PF0*8X> @,,++**%%%%%% %%###### ##          l  0a|߃  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome StatementNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 6} $ } } $ } } $ 0                                 TherapeuticsMD, Inc. 10-Q 08/03/2017 Cash FlowsSix Months Ended    June 30, 2017    June 30, 2016        , $CASH FLOWS FROM OPERATING ACTIVITIES         Net loss ~ C  ~  0 (Adjustments to reconcile net loss to net        0(cash flows used in operating activities:$Depreciation of fixed assets~ "6~ B,)!Amortization of intangible assets~ ~ 5-(Recovery of) provision for doubtful accounts~ ~ rN Share-based compensation~ v=~ 214,Changes in operating assets and liabilities:Accounts receivable~ JD~ r Inventory~ c~ 0Other current assets~ ^l~ =Accounts payable~ B-~ !Other current liabilities~ j~ U-%Net cash used in operating activities~ * ~ ,$CASH FLOWS FROM INVESTING ACTIVITIES Patent costs~ :~  Purchase of fixed assets~ ~ #Payment of security deposit ?~ -%Net cash used in investing activities~ `~ Dlt4r.x]`WVJ ! " # $ % & ' ( ) * + , - . /          ,!$CASH FLOWS FROM FINANCING ACTIVITIES!!!!!!!!/"'Proceeds from sale of common stock, net"" "?"""~ "i' "#of costs*$"Proceeds from exercise of warrants$$~ $^$$$~ $"S$)%!Proceeds from exercise of options%%~ %" %%%~ %;%1&)Net cash provided by financing activities&&~ &~&&&~ & &'''''''''#((Decrease) increase in cash((~ (@(((~ (F(!)Cash, beginning of period))~ )V4\)))~ )\m)*Cash, end of period*~ *u**~ *zU'*+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$6,nZ72s=PF0*8X> @R //..--****     l  ڍ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ }  } $ }  } $                    TherapeuticsMD, Inc. 10-Q 08/03/2017NOTE 4 INVENTORYJune 30, December 31,  ~   ~  Finished product ~ rU  ~ 6@   Raw material  ~ R   ~ R  TOTAL INVENTORY ~ MV  ~ A  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznRocW/=PF0*8X> @Z        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0.} $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 08/03/2017#NOTE 5 OTHER CURRENT ASSETSJune 30, December 31,  ~   ~ # Prepaid manufacturing costs ~ R=  ~ <  Prepaid marketing costs  ~      ?  Prepaid insurance  ~ e   ~ U& . &Prepaid research and development costs   ?   ~  Prepaid consulting ?~  Prepaid vendor deposits~ "N~ ^Other prepaid costs~ 2~ ""TOTAL OTHER CURRENT ASSETS~ N~ R$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2{oc<5c=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 08/03/2017NOTE 6 FIXED ASSETSJune 30, December 31,  ~   ~  Accounting system ~ `  ~ `   Equipment  ~ B   ~ :"   Computer hardware  ~ N   ~ N  Furniture and fixtures  ~    ~  Leasehold improvements~ P~ P~ &/~ - Accumulated depreciation~ ~~  TOTAL FIXED ASSETS~ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2wkNTHP=PF0*8X> @Z      l  E  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } :} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 08/03/2017 NOTE 7 INTANGIBLE ASSETS June 30, 2017   Gross    Accumulated   Net    Weighted-    Carrying    Amortization   Amount   Average   Amount            Remaining                Amortization                Period (yrs.)%Amortizing intangible assets:      OPERA ? software patent~ >~  ~  >~  (@.&Development costs of corporate website~ ~~ f    ?   n/a/'Approved hormone therapy drug candidate~ I~ : ~  mA  /@patents80Hormone therapy drug candidate patents (pending)~ +X ?  ~  +X   n/a)!Non-amortizing intangible assets:     Multiple trademarks~   ?  ~      indefinite Total~ އ~  ~  7  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<~rf)q IA5)=PF0*8X> @             l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETSNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } :} $ }  } $ }  }  $ }  } $ }  } $      TherapeuticsMD, Inc. 10-Q 08/03/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSDecember 31, 2016   Gross    Accumulated   Net    Weighted-    Carrying    Amortization   Amount   Average   Amount            Remaining                Amortization                Period (yrs.)%Amortizing intangible assets:      OPERA ? software patent~ >~  ~  ֍  )@.&Development costs of corporate website~ ~~ f    ?   n/a1)Approved hormone therapy drug candidate~ 2B~   ~  N}<  ~ Bpatents80Hormone therapy drug candidate patents (pending)~ N|I ?  ~  N|I   n/a)!Non-amortizing intangible assets:     Multiple trademarks~ Q  ?  ~  Q    indefinite Total~ ~ : ~  Rْ  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/<nbVJ Q)h =PF0*8X> @            l  "  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } } $      TherapeuticsMD, Inc. 10-Q 08/03/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Year Ending Estimated  December 31,    Amortization  2017(6 months)  ~ +  ~   ~ W  ~   ~ W  ~   ~ W ~ ~ W Thereafter~ `/$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.wnbVJZv*=PF0*8X> @j        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)NOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0} $ } y} $ } y} $                             TherapeuticsMD, Inc. 10-Q 08/03/2017( NOTE 8 OTHER CURRENT LIABILITIESJune 30, December 31,  ~   ~ $ Accrued clinical trial costs ~ 9   ~ 0N / 'Accrued payroll, bonuses and commission  ~ j   ~ Š  costs$ Accrued compensated absences  ~ 9   ~ f( ,$Accrued legal and accounting expense~ >~  )!Accrued sales and marketing costs~ V'~ (Other accrued expenses~ ~w ~  0(Allowance for wholesale distributor fees~ ~ zAccrued royalties~ ~a~ .)!Allowance for coupons and returns~ 6?>~ 0 Accrued rent~ Zv~ ^ ,$ TOTAL OTHER CURRENT LIABILITIES~ ,<~ VV$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/: vj^6nW>1u=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } m} $ } } $ } } $                    TherapeuticsMD, Inc. 10-Q 08/03/2017!NOTE 9 NET LOSS PER SHARE"Three and Six months ended    June 30, 2017    June 30, 2016   Stock options  ~ Y   ~ ƃ  Warrants  ~ .   ~ n    ~ ևR   ~ 2  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qe0H<0=PF0*8X> @2   l  z  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } U} m} $ } m      TherapeuticsMD, Inc. 10-Q 08/03/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSSix Months Ended   June 30, 2017   June 30, 2016 Risk-free interest rate  1.84-2.01%   1.26-1.70%  Volatility  61.56-63.95%   70.44-71.22% Term (in years) 5.5-6.25  @ Dividend yield 0.00%  0.00%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*hnbVJ"}+~V=PF0*8X> @" l  %  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } a/} $ } }  $ } U} $      TherapeuticsMD, Inc. 10-Q 08/03/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS1)Number of Shares Underlying Stock Options'Weighted Average Exercise Price  Weighted  !Aggregate Intrinsic Value           Average            Remaining            Contractual            Life in Years$ Balance at December 31, 2016  ~ 0   {Gz @    333333@  ~ ]l Granted~ Tq= ףp@      Exercised~ (\@     ~ Expired/Forfeited~ )\(@      Balance at June 30, 2017~ YRQ@   ffffff@  ~ o /'Vested and Exercisable at June 30, 2017~ Lw ףp= @   @  ~ NV !Unvested at June 30, 2017~ R Q@   !@  ~ R$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6 nbVJE- -^=PF0*8X> @     l  H  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } I"} $ }  } $      TherapeuticsMD, Inc. 10-Q 08/03/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS!Years Ending December 31, 2017 (6 months)  ~ k ~    ~ j: ~    ~ B ~    ~ C ~    ~ ^9 $Total minimum lease payments~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.wnbVJ\x=PF0*8X> @*  l  '+B.  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4)!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $}  } m} <} m}  '     TherapeuticsMD, Inc. 10-Q 08/03/2017TX-001HR6.Replenish Trial Co-Primary Efficacy Endpoints:0 (Mean Change in Frequency and Severity of4 ,Hot Flashes Per Week Versus Placebo at Weeks% 4 and 12, VMS-MITT Population            Estradiol/Progesterone 1 mg/100 mg 0.5 mg/100 mg 0.5 mg/50 mg 0.25 mg/50 mgPlacebo (n = 141) (n = 149) (n = 147) (n = 154) (n = 135) Frequency%Week 4 P-value versus placebo9v??5^I ?MbP? ?&Week 12 P-value versus placeboMb`? ?Severity%Week 4 P-value versus placeboX9v?{Gzt?Dl?? ?&Week 12 P-value versus placebo;On?~jt? ?0(Replenish Trial Primary Safety Endpoint:6.Incidence of Consensus Endometrial Hyperplasia2*or Malignancy up to 12 months, EndometrialSafety Population?D] lv<_ |+kf-w !"#$%&      !Endometrial Hyperplasia! 0% (0/280)! 0% (0/303)! 0% (0/306)! 0% (0/274)! 0% (0/92)"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/ x(=PF0*8X> @Z &&%%$$    l  <  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $} $ }  } $ }  }  $ } } $ }  } $      TherapeuticsMD, Inc. 10-Q 08/03/2017)!Research and Development ExpensesThree Months Ended  Six Months Ended   June 30,   June 30,  ~   ~   ~   ~     (000s)   (000s)   TX 001-HR ~ T  ~   ~ &  ~    TX 002-HR   ?    ?    ?    ?  TX 004-HR~ >+~ )  ~  I  ~ O&Other research and development~ ~ f,  ~  ",  ~ .e Total~ 2~ F ~    ~ *$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ui](6uM=PF0*8X> @             l  J  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development ExpensOperating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ } U} $ }  }  $ } } $                         TherapeuticsMD, Inc. 10-Q 08/03/2017WOThree months ended June 30, 2017 compared with three months ended June 30, 2016Three Months Ended      June 30,  ~   ~    Change    (000s)   Revenues, net ~ jB  ~ D  ~   Cost of goods sold  ~     ~    ~  Operating expenses~ m~ ~  ~     Operating loss~ *~   ~  n Other income, net~ f~   ~   Net loss~ ~ j ~   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2qSG;/Z==PF0*8X> @z          l  W  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 08/03/2017Operating ExpensesThree Months Ended   June 30,  ~   ~  & Research and development costs   B@ %   @L@ %. &Human resource related costs including   333338@ %   8@ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding human8@ %333333 @ %resource costs/'Professional fees for legal, accountingffffff@ % @ %and consulting Other operating expenses!@ %ffffff@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4Nxl*nF;/#=PF0*8X> @:    l  ^f  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating Expenses!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 6} $ }  } $ }  }  $ } } $                            TherapeuticsMD, Inc. 10-Q 08/03/2017Operating ExpensesThree Months Ended      June 30,  ~   ~    Change    (000s) & Research and development costs ~ 2  ~ F  ~  0 (Human resources related costs, including  ~ fZ   ~ ^   ~ ~ $salaries, benefits and taxes5-Sales and marketing, excluding human resource~ Y~   ~  :  costs/'Professional fees for legal, accounting~ ~    ~   and consulting Other operating expenses~ ~   ~    Total operating expenses~ m~ ~ ~    $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/80 xlX"uiA=PF0*8X> @z          l  rt  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ }  } $ }  }  $ } } $                         TherapeuticsMD, Inc. 10-Q 08/03/2017VN29 Six months ended June 30, 2017 compared with six months ended June 30, 2016Six Months Ended      June 30,  ~   ~    Change    (000s)   Revenues, net ~   ~ ֑  ~   Cost of goods sold  ~    ~ "   ~  Operating expenses~ .~   ~  2  Operating loss~ }~ l  ~  N Other income, net~ n~   ~   Net loss~ ~ bo ~  f $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2nTH<0]@=PF0*8X> @z          l  S  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 08/03/2017Operating ExpensesSix Months Ended   June 30,  ~   ~  & Research and development costs   A@ %   YM@ %/ 'Human resource related costs, including   fffff7@ %  ~ ^ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding human~ r %333333@ %resource costs/'Professional fees for legal, accounting333333@ %@ %and consulting Other operating expenses333333 @ %ffffff@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4Exl,sKD8,=PF0*8X> @:    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $ }  }  $ } U} $                            TherapeuticsMD, Inc. 10-Q 08/03/2017Operating ExpensesSix Months Ended      June 30,  ~   ~    Change    (000s) & Research and development costs ~   ~ *  ~ < 0 (Human resources related costs, including  ~    ~ B   ~  $salaries, benefits and taxes2*Sales and marketing costs, excluding human~ ~ *8  ~   resource costs/'Professional fees for legal, accounting~ +~ !  ~    and consulting Other operating expenses~ <~ 2  ~  f   Total operating expenses~ .~  ~  2 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/84 xlZ$}qe==PF0*8X> @z          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 1} $                      TherapeuticsMD, Inc. 10-Q 08/03/2017-%Summary of (Uses) and Sources of CashSix Months Ended   June 30,  ~   ~     (000s) - %Net cash used in operating activities ~ ڣ  ~ n - %Net cash used in investing activities ~   ~  1)Net cash provided by financing activities~ >~ _$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,U|}qeY_e=PF0*8X> @r         l   !  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of  SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } y } } 6      TherapeuticsMD, Inc. 10-Q 08/03/2017Item 6. ExhibitsExhibit Date Description 31.1* August 3, 20170 (Certification of Chief Executive Officer  5 -pursuant to Rule 13a-14(a) and Rule 15d-14(a) 31.2* August 3, 20170 (Certification of Chief Financial Officer  5 -pursuant to Rule 13a-14(a) and Rule 15d-14(a) 32.1* August 3, 20175 -Section 1350 Certification of Chief ExecutiveOfficer 32.2*August 3, 20175-Section 1350 Certification of Chief FinancialOfficer101.INS* n/aXBRL Instance Document101.SCH* n/a/'XBRL Taxonomy Extension Schema Document101.CAL* n/a4,XBRL Taxonomy Extension Calculation LinkbaseDocument101.DEF* n/a3+XBRL Taxonomy Extension Definition LinkbaseInstance Document101.LAB* n/a.&XBRL Taxonomy Extension Label LinkbaseInstance Document101.PRE* n/a,$XBRL Taxonomy Extension Presentation"Linkbase Instance Document$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/D? lzn4%pEq:{(=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } } U5      TherapeuticsMD, Inc. 10-Q 08/03/2017 SIGNATURESTHERAPEUTICSMD, INC.     By: /s/ Robert G. Finizio   Robert G. Finizio   Chief Executive Officer  % (Principal Executive Officer) By:!/ s/ Daniel A. CartwrightDaniel A. CartwrightChief Financial Officer4,(Principal Financial and Accounting Officer)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6tH$x7`=PF0*8X> @" l  p  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } y#      TherapeuticsMD, Inc. 10-Q 08/03/20170(CERTIFICATION OF CHIEF EXECUTIVE OFFICERAugust 3, 2017/s/ Robert G. Finizio  Robert G. Finizio    Chief Executive Officer % (Principal Executive Officer) $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznbVvj^6=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } U5      TherapeuticsMD, Inc. 10-Q 08/03/20170(CERTIFICATION OF CHIEF FINANCIAL OFFICERAugust 3, 2017 /s/ Daniel A. Cartwright  Daniel A. Cartwright  Chief Financial Officer 4 ,(Principal Financial and Accounting Officer)   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznbVyaUI!=PF0*8X> @ l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIASECTION 1350 CE (1)U } } U      TherapeuticsMD, Inc. 10-Q 08/03/2017=5SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICERAugust 3, 2017/s/ Robert G. Finizio  Robert G. Finizio  Chief Executive Officer  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$3,maUIv=PF0*8X> @  l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? FORM 10QINDEX Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)NOTES TO UNAUDITED (4) TX001HR!Research and Development Expens!Three months ended June 30 2017Operating ExpensesOperating Expen (1)!29 Six months ended June 30 201Operating Expen (2)Operating Expen (3)!Summary of Uses and Sources of Item 6 Exhibits SIGNATURES!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CU } }       TherapeuticsMD, Inc. 10-Q 08/03/2017=5SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICERAugust 3, 2017 /s/ Daniel A. Cartwright  Daniel A. Cartwright  Chief Financial Officer  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$9,maUI p=PF0*8X> @  Root Entry FBook    !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~